Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 6571 AL 6585

Population Pharmacokinetic and Exposure-Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management

Nguyen HQ, Crass RL, Chapel S, Kuan HS, Loewen G, Brar S.

J Clin Pharmacol. 2025 Dec;65(12):1777-1788. doi: 10.1002/jcph.70092. Epub 2025 Aug 12.

Emerging Molecular Targets in Neurodegenerative Disorders: New Avenues for Therapeutic Intervention

Eroglu E, Harmanci N.

Basic Clin Pharmacol Toxicol. 2025 Oct;137(4):e70107. doi: 10.1111/bcpt.70107.

Genetic therapies for movement disorders - current status

Sartorelli J, Ng J, Rahim AA, Waddington SN, Kurian MA.

J Neurol. 2025 Feb 22;272(3):220. doi: 10.1007/s00415-025-12940-5.

Modeling Protein Aggregation Kinetics from NMR Data

Tugarinov V, Torricella F, Ghosh S, Clore GM.

J Mol Biol. 2025 Dec 1;437(23):169269. doi: 10.1016/j.jmb.2025.169269. Epub 2025 Jun 9.

Epigenetic Dysregulation in Neurodegenerative Disease: Implications for Neuropathology and Therapy

Qasim H, Khattab K, Abu Shugaer M, Varrassi G.

Cureus. 2025 Aug 15;17(8):e90188. doi: 10.7759/cureus.90188. eCollection 2025 Aug.

Neuroinflammation and neurodegeneration in Huntington's disease: genetic hallmarks, role of metals and organophosphates

Kunwar OK, Singh S.

Neurogenetics. 2025 Jan 17;26(1):21. doi: 10.1007/s10048-025-00801-2.

Computer Vision Technologies in Movement Disorders: A Systematic Review

Pecoraro PM, Marsili L, Espay AJ, Bologna M, di Biase L.

Mov Disord Clin Pract. 2025 Sep;12(9):1229-1243. doi: 10.1002/mdc3.70123. Epub 2025 May 6.

Pharmacological Treatment of Neuropsychiatric Symptoms in Huntington's Disease: A Systematic Review

Andriessen RL, Oosterloo M, Molema J, Daemen MMJ, Linden DEJ, Leentjens AFG.

Mov Disord Clin Pract. 2025 Apr;12(4):418-431. doi: 10.1002/mdc3.14343. Epub 2025 Jan 31.

Unraveling Berberine's Molecular Mechanisms in Neuroprotection Against Neurodegeneration

Begh MZA, Amin MA, Shatu MM, Sweilam SH, Puri S, Ramesh RB, Arjun UVNV, Shanmugarajan TS, Pommala N, Durairaj A, Ethiraj S, Shenbakadurai N, Ahmad I, Emran TB.

Chem Biodivers. 2025 Aug;22(8):e202500170. doi: 10.1002/cbdv.202500170. Epub 2025 Apr 12.

Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders

Sivalingam AM, Sureshkumar DD.

Mol Neurobiol. 2025 Jun;62(6):7576-7596. doi: 10.1007/s12035-025-04733-8. Epub 2025 Feb 7.

Brain-Derived Neurotrophic Factor (BDNF) in Huntington's Disease: Neurobiology and Therapeutic Potential

Azman KF, Zakaria R.

Curr Neuropharmacol. 2025;23(4):384-403. doi: 10.2174/1570159X22666240530105516.

Activity and Heterogeneity of Astrocytes in Neurological Diseases: Molecular Mechanisms and Therapeutic Targets

Mao S, Qiao R, Wang Q, Shen L, Li D, Huo X, Wang J, Liu K, Chen W, Zhu T, Zhang B, Leng S, Bai Y.

MedComm (2020). 2025 Aug 22;6(9):e70329. doi: 10.1002/mco2.70329. eCollection 2025 Sep.

The role of astrocytes in human Huntington's disease pathology

Al-Dalahmah O, Goldman JE.

J Huntingtons Dis. 2025 Aug;14(3):214-228. doi: 10.1177/18796397251344173. Epub 2025 Aug 7.

Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease

Tripathi S, Sharma Y, Kumar D.

Curr Rev Clin Exp Pharmacol. 2025;20(4):269-288. doi: 10.2174/0127724328312991241001051813.

Is the Voltage-Dependent Anion Channel a Major Player in Neurodegenerative Diseases?

Neumann S, Heumann R.

Int J Mol Sci. 2025 Jun 26;26(13):6138. doi: 10.3390/ijms26136138.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias